Skip to main content

Table 2 Baseline demographic and clinical characteristics of study subjects depending on reinfection

From: Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy

  EBMT MEA
Variable category Total (59, 100%) Reinfected group (7, 11.9%) Continuously eradicated group (52, 88.1%) p-value* Total (116, 100%) Reinfected group (19, 16.4%) Continuously eradicated group (97, 83.6%) p-value*
Gender (N = 59) (n = 7) (n = 52)   (N = 116) (n = 19) (n = 97)  
  Male (35, 59.3%) (4, 57.1%) (31, 59.6%) 0.816 (69, 59.5%) (12, 63.2%) (57, 58.8%) 0.353
  Female (24, 40.7%) (3, 42.9%) (21, 40.4%)   (47, 40.5%) (7, 36.8%) (40, 41.2%)  
Age (mean ± SD) (N = 59) (n = 7) (n = 52)   (N = 116) (n = 19) (n = 97)  
(56.1 ± 9.3) (59.9 ± 9.8) (55.6 ± 9.2) (56.8 ± 9.5) (56.7 ± 9.4) (56.8 ± 9.6)
  20-29 (1, 1.7%) (0, 0.0%) (1, 1.9%) 0.306 (1, 0.9%) (0, 0.0%) (1, 1.0%) 0.479
  30-39 (1, 1.7%) (0, 0.0%) (1, 1.9%)   (3, 2.6%) (0, 0.0%) (3, 3.1%)  
  40-49 (13, 22.0%) (2, 22.2%) (11, 21.2%)   (21, 18.1%) (6, 31.6%) (15, 15.5%)  
  50-59 (21, 35.6%) (1, 14.3%) (20, 38.5%)   (40, 34.5%) (5, 26.3%) (35, 36.1%)  
  60-69 (20, 33.9%) (3, 42.9%) (17, 32.7%)   (42, 36.2%) (6, 31.6%) (36, 37.1%)  
  70-79 (3, 5.1%) (1, 14.3%) (2, 3.8%)   (8, 10.5%) (2, 10.5%) (6, 6.2%)  
  80-89 (0, 0.0%) (0, 0.0%) (0, 0.0%)   (1, 0.6%) (0, 0.0%) (1, 1.0%)  
Clinical diagnosis (N = 59) (n = 7) (n = 52)   (N = 116) (n = 19) (n = 97)  
  Early gastric cancer (11, 18.6%) (0, 0.0%) (11, 21.2%) 0.198 (29, 25.0%) (7, 36.8%) (22, 22.7%) 0.77
  Dysplasia (3, 5.1%) (1, 14.3%) (2, 3.8%)   (16, 13.8%) (3, 15.8%) (13, 13.4%)  
  Peptic ulcer disease (17, 28.8%) (4, 57.1%) (13, 25.0%)   (17, 14.7%) (3, 15.8%) (14, 14.4%)  
  Chronic gastritis (28, 47.5%) (2, 28.6%) (26, 50.0%)   (54, 46.6%) (6, 31.6%) (48, 49.5%)  
Histological AG in either antrum or body (N = 37) (n =6) (n = 31)   (N = 79) (n = 14) (n = 65)  
  Yes (21, 56.8%) (5, 83.3%) (16, 51.6%) 0.113 (46, 58.2%) (9, 64.3%) (37, 56.9%) 0.575
  No (16, 43.2%) (1, 16.7%) (15, 48.4%)   (33, 41.8%) (5, 35.7%) (28, 43.1%)  
Histological IM in either antrum or body (N = 47) (n = 6) (n = 41)   (N = 97) (n = 15) (n = 82)  
  Yes (23, 48.9%) (4, 66.7%) (21, 51.2%) 0.193 (61, 62.9%) (8, 53.3%) (53, 64.6%) 0.52
  No (24, 51.1%) (2, 33.3%) (20, 48.8%)   (36, 37.1%) (7, 46.7%) (29, 35.4%)  
  1. EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d); MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.); AG, atrophic gastritis; IM, intestinal metaplasia.
  2. All of early gastric cancer patients were cured by endoscopic submucosal dissection.
  3. * P-value for Log-rank test.